Tag: AML

Bio-Path Announces Clinical Update to Interim Analysis of Phase 2 Prexigebersen Trial in Acute Myeloid Leukemia

Bio-Path Holdings (NASDAQ:BPTH) has announced a clinical update on its interim analysis from the Phase 2 trial of prexigebersen (BP1001)...

Aptose Provides Molecule Update and Q1 Financial Results

Aptose Bioscience is the only company with a small molecule in development without those toxicities for AML patients with its...